Insider Selling: Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) EVP Sells 5,214 Shares of Stock

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) EVP Yakob Liawatidewi sold 5,214 shares of the stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $52.05, for a total transaction of $271,388.70. Following the sale, the executive vice president now owns 74,938 shares of the company’s stock, valued at approximately $3,900,522.90. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Amphastar Pharmaceuticals Stock Up 4.8 %

AMPH stock traded up $2.22 during midday trading on Friday, reaching $48.31. 626,882 shares of the company’s stock traded hands, compared to its average volume of 397,490. The company has a quick ratio of 2.63, a current ratio of 3.52 and a debt-to-equity ratio of 0.82. The firm’s fifty day moving average price is $48.45 and its 200-day moving average price is $44.13. Amphastar Pharmaceuticals, Inc. has a 52 week low of $36.56 and a 52 week high of $65.92. The company has a market cap of $2.35 billion, a price-to-earnings ratio of 15.43, a P/E/G ratio of 0.97 and a beta of 0.82.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its earnings results on Wednesday, August 7th. The company reported $0.85 earnings per share for the quarter, topping analysts’ consensus estimates of $0.75 by $0.10. The company had revenue of $182.39 million for the quarter, compared to analyst estimates of $171.29 million. Amphastar Pharmaceuticals had a net margin of 23.36% and a return on equity of 29.79%. As a group, sell-side analysts forecast that Amphastar Pharmaceuticals, Inc. will post 3.67 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have weighed in on AMPH shares. StockNews.com downgraded Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, November 1st. Needham & Company LLC reiterated a “hold” rating on shares of Amphastar Pharmaceuticals in a research report on Thursday, August 8th. Finally, Piper Sandler reduced their price target on shares of Amphastar Pharmaceuticals from $71.00 to $66.00 and set an “overweight” rating for the company in a report on Thursday, August 8th. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat, Amphastar Pharmaceuticals has a consensus rating of “Hold” and an average target price of $63.00.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Mutual of America Capital Management LLC grew its holdings in Amphastar Pharmaceuticals by 11.3% during the first quarter. Mutual of America Capital Management LLC now owns 97,683 shares of the company’s stock worth $4,289,000 after buying an additional 9,926 shares in the last quarter. BI Asset Management Fondsmaeglerselskab A S raised its holdings in shares of Amphastar Pharmaceuticals by 62.9% in the first quarter. BI Asset Management Fondsmaeglerselskab A S now owns 12,455 shares of the company’s stock valued at $547,000 after purchasing an additional 4,811 shares during the last quarter. Texas Permanent School Fund Corp lifted its position in shares of Amphastar Pharmaceuticals by 1.3% during the first quarter. Texas Permanent School Fund Corp now owns 32,704 shares of the company’s stock valued at $1,436,000 after purchasing an additional 424 shares in the last quarter. Quantbot Technologies LP purchased a new position in Amphastar Pharmaceuticals during the first quarter worth about $481,000. Finally, Concurrent Investment Advisors LLC bought a new stake in Amphastar Pharmaceuticals in the 1st quarter worth about $693,000. Institutional investors own 65.09% of the company’s stock.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.